Neuphoria Therapeutics (NEUP) Operating Expenses (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Operating Expenses for 4 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Operating Expenses fell 59.92% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $16.7 million, a 1.9% increase from a year earlier, with the FY2025 full-year figure at $16.8 million, down 6.23% from the prior year.
• Operating Expenses was $1.2 million for Q1 2026 at Neuphoria Therapeutics, down from $4.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $5.8 million in Q2 2025 and troughed at $1.2 million in Q1 2026.
• A 4-year average of $4.1 million and a median of $4.4 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 58.44% in 2025 and slumped 59.92% in 2026, its largest moves.
• Over 4 years, Operating Expenses stood at $4.6 million in 2023, then dropped by 4.1% to $4.4 million in 2024, then dropped by 6.99% to $4.1 million in 2025, then plunged by 70.16% to $1.2 million in 2026.
• The last three Operating Expenses figures came in at $1.2 million (Q1 2026), $4.1 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.